Mezlocillin
File:Mezlocillin.svg | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Intravenous, intramuscular |
ATC code | |
Pharmacokinetic data | |
Protein binding | 16–59% |
Metabolism | Hepatic (20–30%) |
Elimination half-life | 1.3–4.4 hours |
Excretion | Renal (50%) and biliary |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C21H25N5O8S2 |
Molar mass | 539.584 g/mol |
WikiDoc Resources for Mezlocillin |
Articles |
---|
Most recent articles on Mezlocillin Most cited articles on Mezlocillin |
Media |
Powerpoint slides on Mezlocillin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mezlocillin at Clinical Trials.gov Clinical Trials on Mezlocillin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mezlocillin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mezlocillin Discussion groups on Mezlocillin Patient Handouts on Mezlocillin Directions to Hospitals Treating Mezlocillin Risk calculators and risk factors for Mezlocillin
|
Healthcare Provider Resources |
Causes & Risk Factors for Mezlocillin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Mezlocillin is a broad-spectrum penicillin antibiotic. It is active against both Gram-negative and some Gram-positive bacteria.
Mechanism of action
Like all other beta-lactam antibiotics, mezlocillin inhibits the third and last stage of bacterial cell wall synthesis by binding to penicillin binding proteins. This ultimately leads to cell lysis.
Susceptible organisms
Gram-negative
- Bacteroides spp., including B. fragilis
- Enterobacter spp.
- Escherichia coli
- Haemophilus influenzae
- Klebsiella species
- Morganella morganii
- Neisseria gonorrhoeae
- Proteus mirabilis
- Proteus vulgaris
- Providencia rettgeri
- Pseudomonas spp., including P. aeruginosa
- Serratia marcescens
Gram-positive
External links
- Template:DiseasesDB
- Template:GPnotebook
- Duke
- Kristof R, Clusmann H, Koehler W, Fink K, Schramm J (1998). "Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange". J Neurol Neurosurg Psychiatry. 64 (3): 379–81. PMID 9527154.
- McCormick P, Greenslade L, Kibbler C, Chin J, Burroughs A, McIntyre N (1997). "A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients". Hepatology. 25 (4): 833–6. PMID 9096584.
- Rohde B, Werner U, Hickstein H, Ehmcke H, Drewelow B (1997). "Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure". Eur J Clin Pharmacol. 53 (2): 111–5. PMID 9403281.
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list
- Beta-lactam antibiotics